LIAN LianBio

FDA Catalyst Company
2.47
+0.01  (+0%)
Previous Close 2.46
Open 2.56
52 Week Low 2.15
52 Week High 16.37
Market Cap $267,440,381
Shares 108,275,458
Float 108,169,322
Enterprise Value $-98,058,374
Volume 141,734
Av. Daily Volume 700,371
Live cash est $88,666,444,222
Cash Burn N/A
No. Mths Cash 12
Insiders % 0.2
Total debt to equity 4.35
Earnings Date 01/01/2001
EPS EST. 1.82
EPS PRIOR. 1.82
EPS 1.82
Rev guidance $10,459,000,000

Biotech Analyst Ratings

Analyst Action Rating Now PT Prior PT Now Last Updated
Goldman Sachs Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 11/26/2021
Jefferies Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 11/26/2021
Raymond James Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 11/24/2021

Latest News

    • LianBio's partner, Bristol Myers Squibb, has received U.S. FDA approval of mavacamten for the treatment of patients with obstructive hypertrophic cardiomyopathy (oHCM)

    • Registrational Phase 3 EXPLORER-CN clinical trial of mavacamten in Chinese patients with symptomatic oHCM ongoing

    • LianBio's partner, Tarsus, announced positive topline data from the Phase 3 Saturn-2 clinical trial of TP-03 in patients with Demodex blepharitis

    • LianBio's partner, ReViral, entered into definitive agreement to be acquired by Pfizer

    • Three additional pipeline programs expected to enter into registrational Phase 3 clinical trials in China by year-end 2022

    • Cash balance of $389.1 million at the end of first quarter 2022 with runway through mid- 2024

    SHANGHAI, China and…

    View Full Article
  1. Mavacamten demonstrated a favorable safety, tolerability and pharmacokinetic profile in healthy Chinese volunteers

    Study was conducted in parallel with ongoing Phase 3 EXPLORER-CN trial of mavacamten in obstructive hypertrophic cardiomyopathy to support regulatory approval in China

    SHANGHAI, China and PRINCETON, N.J., May 09, 2022 (GLOBE NEWSWIRE) -- LianBio (NASDAQ:LIAN) a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced the completion of a Phase 1 pharmacokinetic study of mavacamten in healthy Chinese volunteers.

    A single oral administration of mavacamten showed no new safety signals in Chinese healthy adult subjects. The data demonstrated a favorable…

    View Full Article
  2. SHANGHAI, China and PRINCETON, N.J., May 05, 2022 (GLOBE NEWSWIRE) --  LianBio (NASDAQ:LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that management will participate in the Bank of America Securities 2022 Healthcare Conference being held in person in Las Vegas on May 10-13, 2022. Management is scheduled to participate in a fireside chat on May 12, 2022 at 9:20 a.m.

    A live audio webcast of the fireside chat will be accessible from the Investors section of LianBio's website at https://investors.lianbio.com/ with a replay available following the live event.

    About LianBio

    LianBio is a cross-border biotechnology company on a mission to bring transformative…

    View Full Article
  3. SHANGHAI, China and PRINCETON, N.J., May 03, 2022 (GLOBE NEWSWIRE) -- LianBio's (NASDAQ:LIAN) partner, Tarsus Pharmaceuticals, Inc. (Tarsus) yesterday announced that TP-03 (lotilaner ophthalmic solution, 0.25%) met the primary endpoint and all secondary endpoints in the Saturn-2 pivotal Phase 3 trial with a favorable safety profile, reinforcing its potential to resolve Demodex blepharitis, a highly prevalent eyelid disease. With these results, Tarsus plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the second half of 2022.

    "We congratulate our partner Tarsus on continuing to demonstrate clinically meaningful and statistically significant disease resolution in the second pivotal trial of TP-03…

    View Full Article
  4. SHANGHAI and PRINCETON, N.J., April 29, 2022 (GLOBE NEWSWIRE) -- LianBio's (NASDAQ:LIAN) partner, Bristol Myers Squibb, announced yesterday that the U.S. Food and Drug Administration (FDA) approved Camzyos™ (mavacamten, 2.5 mg, 5 mg, 10 mg and 15 mg capsules) for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (obstructive HCM) to improve functional capacity and symptoms. Camzyos is the first and only FDA-approved allosteric and reversible inhibitor selective for cardiac myosin that targets the underlying pathophysiology of obstructive HCM.

    LianBio licensed rights from MyoKardia, now a wholly owned subsidiary of Bristol Myers Squibb, in August 2020 for the development…

    View Full Article
View All LianBio News